Table 6.
Pharmacologic treatment during HSS admission
| Overall | COVID floor admit | COVID ICU admit | Other admit | |
|---|---|---|---|---|
| N | 148 | 111 | 19 | 18 |
| Hydroxychloroquine (%) | 7 (4.7) | 5 (4.5) | 0 (0.0) | 2 (11.1) |
| Tocilizumab (%) | 4 (2.7) | 1 (0.9) | 2 (10.5) | 1 (5.6) |
| Remdesivir (%) | 4 (2.7) | 1 (0.9) | 3 (15.8) | 0 (0.0) |
| Convalescent plasma (%) | 6 (4.1) | 3 (2.7) | 3 (15.8) | 0 (0.0) |
| IVIG (%) | 4 (2.7) | 2 (1.8) | 2 (10.5) | 1 (5.6) |
| Vasopressors (%) | 23 (15.5) | 2 (1.8) | 15 (78.9) | 6 (33.3) |
IVIG intravenous immunoglobulin